Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye

Colloids and Surfaces B: Biointerfaces

Volumn 88, Issue 1, 2011, Pages 150-157

  Araújo, Joana ^a   Nikolic, Sasha ^a   Egea, Maria A ^a   Souto, Eliana B ^b,c   Garcia, Maria L ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Eye; Nanostructured lipid carrier; Nile red; Ocular; Posterior segment; Retina; Stability; Triamcinolone acetonide; Turbiscan

Indexed keywords

EYE; NANOSTRUCTURED LIPID CARRIER; NILE RED; OCULAR; POSTERIOR SEGMENT; RETINA; TRIAMCINOLONE ACETONIDE; TURBISCAN;

AGGLOMERATION; BIOCHEMISTRY; DRUG THERAPY; MAMMALS;

ACETONE;

EYE DROPS; SOLID LIPID NANOPARTICLE; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SHELF LIFE; SINGLE DRUG DOSE; THERMODYNAMICS;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; FEMALE; HUMANS; LIPIDS; MICE; MICROSCOPY, FLUORESCENCE; NANOSTRUCTURES; RETINA; TRIAMCINOLONE ACETONIDE; X-RAY DIFFRACTION;

MUS;

EID: 80052103054     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2011.06.025     Document Type: Article

References (25)

1. Edelhauser H.F., Boatright J.H., Nickerson J.M. Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest. Ophthalmol. Vis. Sci. 2008, 49:4712-4720.
2. Choonara Y.E., Pillay V., Carmichael T.R., Meyer L.C., Du Toit L.C., Naylor S., Wanblad C. In vivo evaluation of a biodegradable donut-shaped minitablet for prolonged posterior segment drug delivery in the rabbit eye model. J. Pharm. Sci. 2011, 100:1819-1832.
3. Yilmaz T., Cordero-Coma M., Lavaque A.J., Gallagher M.J., Padula W.V. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy. Curr. Pharm. Biotechnol. 2011, 12:337-346.
4. Zarbin M.A., Montemagno C., Leary J.F., Ritch R. Nanotechnology in ophthalmology. Can. J. Ophthalmol. 2010, 45:457-476.
5. Diebold Y., Calonge M. Applications of nanoparticles in ophthalmology. Prog. Retin. Eye Res. 2010, 29:596-609.
6. Araujo J., Gonzalez E., Egea M.A., Garcia M.L., Souto E.B. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 2009, 5:394-401.
7. Souto E.B., Muller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Handb. Exp. Pharmacol. 2010, 115-141.
8. Hironaka K., Inokuchi Y., Tozuka Y., Shimazawa M., Hara H., Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J. Control. Release 2009, 136:247-253.
9. Doktorovova S., Araujo J., Garcia M.L., Rakovsky E., Souto E.B. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf. B: Biointerfaces 2010, 75:538-542.
10. Kaneko F., Yano J., Sato K. Diversity in the fatty-acid conformation and chain packing of cis-unsaturated lipids. Curr. Opin. Struct. Biol. 1998, 8:417-425.
11. R.H. Müller, J.S. Lucks, Arzneistoffträger aus festen Lipidteilchen: Feste Lipidnanosphären (SLN), European Patent EP0605497 (1996).
12. Roland I., Piel G., Delattre L., Evrard B. Systematic characterization of oil-in-water emulsions for formulation design. Int. J. Pharm. 2003, 263:85-94.
13. Lemarchand C., Couvreur P., Vauthier C., Costantini D., Gref R. Study of emulsion stabilization by graft copolymers using the optical analyzer Turbiscan. Int. J. Pharm. 2003, 254:77-82.
14. Lombardi Borgia S., Regehly M., Sivaramakrishnan R., Mehnert W., Korting H.C., Danker K., Roder B., Kramer K.D., Schafer-Korting M. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J. Control. Release 2005, 110:151-163.
15. Huang Z.R., Hua S.C., Yang Y.L., Fang J.Y. Development and evaluation of lipid nanoparticles for camptothecin delivery: a comparison of solid lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. Acta. Pharmacol. Sin. 2008, 29:1094-1102.
16. Bunjes H., Koch M.H., Westesen K. Influence of emulsifiers on the crystallization of solid lipid nanoparticles. J. Pharm. Sci. 2003, 92:1509-1520.
17. Martini S., Herrera M.L. Physical properties of shortenings with low-trans fatty acids as affected by emulsifiers and storage conditions. Eur. J. Lipid Sci. Technol. 2008, 110:172-182.
18. Souto E.B., Doktorovová S., Boonme P. Lipid nanocarriers-based semisolids: review on materials and end product formulations. J. Drug Deliv. Sci. Technol. 2011, 21:43-54.
19. Mengual O., Meunier G., Cayre I., Puech K., Snabre P. TURBISCAN MA 2000: multiple light scattering measurement for concentrated emulsion and suspension instability analysis. Talanta 1999, 50:445-456.
20. Freitas C., Muller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
21. Vivek K., Reddy H., Murthy R.S. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS PharmSciTech. 2007, 8:E83.
22. Zhang X., Pan W., Gan L., Zhu C., Gan Y., Nie S. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. (Tokyo) 2008, 56:1645-1650.
23. Westesen W., Siekmann B., Koch M. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int. J. Pharm. 1993, 93:189-199.
24. Bunjes H., Westesen K., Koch M. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 1996, 129:159-173.
25. Bu H.Z., Gukasyan H.J., Goulet L., Lou X.J., Xiang C., Koudriakova T. Ocular disposition, pharmacokinetics, efficacy and safety of nanoparticle-formulated ophthalmic drugs. Curr. Drug Metab. 2007, 8:91-107.